摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

Boron tribromide dichloromethane

中文名称
——
中文别名
——
英文名称
Boron tribromide dichloromethane
英文别名
dichloromethane;tribromoborane
Boron tribromide dichloromethane化学式
CAS
——
化学式
BBr3*2CH2Cl2
mdl
——
分子量
420.389
InChiKey
USLKCMBGQFYUFI-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.58
  • 重原子数:
    7
  • 可旋转键数:
    0
  • 环数:
    0.0
  • sp3杂化的碳原子比例:
    1.0
  • 拓扑面积:
    0
  • 氢给体数:
    0
  • 氢受体数:
    0

反应信息

  • 作为反应物:
    描述:
    Boron tribromide dichloromethane 、 N-[3,5-bis(trifluoromethyl)phenyl]-2-methoxy-4-phenylbenzamide 在 、 Brine 、 magnesium sulfate 、 silica gel 、 正己烷乙酸乙酯 作用下, 以 二氯甲烷乙酸乙酯 为溶剂, 反应 1.0h, 以to give the title compound (69.3 mg, 71.6%) as a white powder的产率得到N-[3,5-bis(trifluoromethyl)phenyl]-2-hydroxy-4-phenylbenzamide
    参考文献:
    名称:
    Nf-kb activation inhibitors
    摘要:
    一种药物具有抑制NF-κB活化作用,其包括以下通式(I)所表示的化合物或其药学上可接受的盐、水合物和溶剂化物作为活性成分,其中A代表氢原子或乙酰基,E代表2,5-二取代或3,5-二取代苯基或单环或融合的多环杂环芳基,其可以被取代,但在所述杂环芳基是{圆圈(1)}在公式(I)中直接结合—CONH—基团的环为苯环的融合多环杂环芳基,{圆圈(2)}未取代的噻唑-2-基团,或者{圆圈(3)}未取代的苯并噻唑-2-基团时,不包括该化合物,环Z代表一个芳香烃,除了由公式—O-A所表示的基团外,它也可以有一个或多个取代基,其中A具有与上述定义相同的含义,公式—CONH-E所表示的基团E具有与上述定义相同的含义。
    公开号:
    US20060089395A1
  • 作为试剂:
    描述:
    1,3-二叔丁基咪唑-2-叉Boron tribromide dichloromethane氢气 作用下, 以 正己烷 为溶剂, -60.0 ℃ 、300.01 kPa 条件下, 生成 1,3-di-tert-butylimidazolium bromide
    参考文献:
    名称:
    Carbene-Based Lewis Pairs for Hydrogen Activation
    摘要:
    我们研究了一系列路易斯酸-碱对,其中含有对立体要求较高的烯碳化合物,这些化合物具有潜在的可逆性,可用于氢气储存。当使用富电子硼烷作为亲电体时,咪唑阳离子会被还原成 2H-咪唑啉(氨基)。通过用强还原剂还原咪唑阳离子,可独立合成氨基化合物。研究还发现,碳化物可作为氢活化的亲电体。初步结果表明,在这些体系中使用氢气作为还原剂,可以将醇还原成烷烃。最后,还证明了过渡金属可以作为亲电体,通过异解裂解激活氢。
    DOI:
    10.1071/ch11246
点击查看最新优质反应信息

文献信息

  • Reactivity to Lewis acids of half-sandwich pentamethylcyclopentadienyl complexes of ruthenium(II) containing chiral diphosphines
    作者:Franco Morandini、Ingrid Munari、Marzia Panese、Antonio Ravazzolo、Giambattista Consiglio
    DOI:10.1016/j.ica.2005.01.027
    日期:2005.6
    Compounds (η5-C5Me5)Ru(L∧L)Cl (where L∧L is 1,2-bis(diphenylphosphino)ethane or chiral homologs thereof) form adducts with BCl3 and BBr3 with 1:2 stoichiometry, whereas no stable compounds are obtained with AlX3 (X = Cl, Br).
    化合物(η 5 -C 5我5)的Ru(L ∧ L)氯(其中L ∧ L是1,2-双(二苯基膦基)乙烷或它们的手性同源物)形成加合物与Bcl 3和的BBr 3以1:2的化学计量,而用AlX 3(X = Cl,Br)则无法获得稳定的化合物。
  • N-benzyldioxothiazolidylbenzamide derivatives and processes for
    申请人:Kyorin Pharameuticals Co., Ltd.
    公开号:US06001862A1
    公开(公告)日:1999-12-14
    The present invention provides novel N-benzyldioxothiazolidylbenzamide derivatives that improve the insulin resistance and have potent hypoglycemic and lipid-lowering effects and processes for preparing the same, and relates to N-benzyldioxothiazolidylbenzamide derivatives characterized by being represented by a general formula (1) ##STR1## [wherein R.sup.1 and R.sup.2 denote identically or differently hydrogen atoms, lower alkyl groups with carbon atoms of 1 to 4, lower alkoxy groups with carbon atoms of 1 to 3, lower haloalkyl groups with carbon atoms of 1 to 3, lower haloalkoxy groups with carbon atoms of 1 to 3, halogen atoms, hydroxyl groups, nitro groups, amino groups which may be substituted with lower alkyl group(s) with carbon atoms of 1 to 3 or hetero rings, or R.sup.1 and R.sup.2 link to form a methylenedioxy group, R.sup.3 denotes a lower alkoxy group with carbon atoms of 1 to 3, hydroxyl group or halogen atom, and dotted line indicates double bond or single bond in combination with solid line], and processes for preparing the same.
    本发明提供了新型N-苄基二氧噻唑基苯甲酰胺衍生物,其改善胰岛素抵抗并具有强效的降血糖和降脂作用,并提供了制备它们的方法。涉及到的N-苄基二氧噻唑基苯甲酰胺衍生物的特征在于由通式(1)表示: 其中R^1和R^2表示相同或不同的氢原子,具有1到4个碳原子的低碳基,具有1到3个碳原子的低碳氧基,具有1到3个碳原子的低卤代烷基,具有1到3个碳原子的低卤代氧基,卤素原子,羟基,硝基,氨基(可以用具有1到3个碳原子的低碳基或杂环代替的氨基),或R^1和R^2连接形成亚甲二氧基基团,R^3表示具有1到3个碳原子的低碳氧基,羟基或卤素原子,虚线表示双键或与实线结合的单键。同时还提供了制备它们的方法。
  • Negative radiation-sensitive resin composition
    申请人:——
    公开号:US20010006758A1
    公开(公告)日:2001-07-05
    A negative radiation-sensitive resin composition including (A) an alkali-soluble resin containing a copolymer selected from the group consisting of a hydroxystyrene/styrene copolymer having hydroxystyrene units in a content of from 65 to 90 mol % and a hydroxystyrene/&agr;-methylstyrene copolymer having hydroxystyrene units in a content of from 65 to 90 mol %, (B) a radiation-sensitive acid-generating agent containing a hydroxyl group-containing onium salt compound, and (C) a cross-linking agent containing an N-(alkoxymethyl)glycoluril compound. The composition is suitable as a chemically amplified negative resist, to which alkaline developing solutions having usual concentration are applicable and which can form, in usual line-and-space patterns, resist patterns having a rectangular cross-sectional shape in a high resolution and also has superior sensitivity, developability and dimensional fidelity.
    一种负型辐射敏感树脂组合物,包括(A)一种可溶于碱性溶液的树脂,其中包含一种共聚物,所述共聚物选自羟基苯乙烯/苯乙烯共聚物,其中羟基苯乙烯单元的含量为65至90摩尔%,以及羟基苯乙烯/α-甲基苯乙烯共聚物,其中羟基苯乙烯单元的含量为65至90摩尔%;(B)一种辐射敏感的酸发生剂,其中包含一种含有羟基基团的阳离子盐化合物;以及(C)一种交联剂,其中包含一种N-(烷氧甲基)脲基乙醇化合物。该组合物适用于化学放大负型光阻,可应用于通常浓度的碱性显影液,并能形成具有高分辨率的矩形横截面形状的线与空间图案的光阻图案,同时具有优异的敏感性、显影性和尺寸保真度。
  • Nf-kb activation inhibitors
    申请人:Muto Susumu
    公开号:US20060089395A1
    公开(公告)日:2006-04-27
    A medicament having inhibitory activity against NF-κB activation which comprises as an active ingredient a substance selected from the group consisting of a compound represented by the following general formula (I) and a pharmacologically acceptable salt thereof, and a hydrate thereof and a solvate thereof: wherein A represents hydrogen atom or acetyl group, E represents a 2,5-di-substituted or a 3,5-di-substituted phenyl group, or a monocyclic or a fused polycyclic heteroaryl group which may be substituted, provided that the compound wherein said heteroaryl group is circle around (1)} a fused polycyclic heteroaryl group wherein the ring which binds directly to —CONH— group in the formula (I) is a benzene ring, circle around (2)} unsubstituted thiazol-2-yl group, or circle around (3)} unsubstituted benzothiazol-2-yl group is excluded, ring Z represents an arene which may have one or more substituents in addition to the group represented by formula —O-A wherein A has the same meaning as that defined above and the group represented by formula —CONH-E wherein E has the same meaning as that defined above, or a heteroarene which may have one or more substituents in addition to the group represented by formula —O-A wherein A has the same meaning as that defined above and the group represented by formula —CONH-E wherein E has the same meaning as that defined above.
    一种药物具有抑制NF-κB活化作用,其包括以下通式(I)所表示的化合物或其药学上可接受的盐、水合物和溶剂化物作为活性成分,其中A代表氢原子或乙酰基,E代表2,5-二取代或3,5-二取代苯基或单环或融合的多环杂环芳基,其可以被取代,但在所述杂环芳基是圆圈(1)}在公式(I)中直接结合—CONH—基团的环为苯环的融合多环杂环芳基,圆圈(2)}未取代的噻唑-2-基团,或者圆圈(3)}未取代的苯并噻唑-2-基团时,不包括该化合物,环Z代表一个芳香烃,除了由公式—O-A所表示的基团外,它也可以有一个或多个取代基,其中A具有与上述定义相同的含义,公式—CONH-E所表示的基团E具有与上述定义相同的含义。
  • Treating syndrome X with substituted tetralins and indanes
    申请人:Chen Xiaoli
    公开号:US20060094786A1
    公开(公告)日:2006-05-04
    The invention features tetralin and indane compounds, compositions containing them, and methods of using them as PPAR alpha modulators to treat or inhibit the progression of, for example, diabetes.
    这项发明涉及四氢萘和茚烷化合物、含有它们的组合物以及将它们用作PPAR alpha调节剂的方法,用于治疗或抑制糖尿病等疾病的进展。
查看更多